SLC5A2 and type 2 diabetes mellitus: On one hand, the correlation of the circulating kallistatin level with glycemic status and atherogenic lipoproteins in T2D underlines the importance of intensive and permanent glucose and lipid control and emphasizes the role of the new classes of agents, such as the glucagon-like peptide-1 receptor agonists and the sodium-glucose cotransporter-2 inhibitors, as well as the use of statins to moderate the atherosclerotic process.